NA
WST icon

Navellier & Associates’s West Pharmaceutical WST Stock Holding History

Navellier & Associates’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-41,237
Closed -$16.9M – 331
2022
Q1 		$16.9M Sell
41,237
-1,639
-4% -$642K 2.88% 2
2021
Q4 		$20.1M Buy
42,876
+209
+0.5% +$90K 2.93% 2
2021
Q3 		$18.1M Buy
42,667
+19,972
+88% +$8.42M 2.73% 2
2021
Q2 		$8.15M Buy
22,695
+1,761
+8% +$582K 1.23% 15
2021
Q1 		$5.9M Buy
20,934
+2,667
+15% +$763K 1.06% 28
2020
Q4 		$5.17M Buy
18,267
+2,044
+13% +$574K 0.94% 31
2020
Q3 		$4.46M Buy
+16,223
New +$4.29M 0.97% 31
2017
Q2 		– Sell
-55,652
Closed -$4.54M – 333
2017
Q1 		$4.54M Buy
55,652
+1,979
+4% +$165K 0.66% 60
2016
Q4 		$4.55M Sell
53,673
-5,992
-10% -$471K 0.75% 47
2016
Q3 		$4.45M Buy
59,665
+6,344
+12% +$504K 0.64% 56
2016
Q2 		$4.05M Buy
+53,321
New +$3.88M 0.6% 52
2014
Q1 		– Sell
-47,472
Closed -$2.33M – 351
2013
Q4 		$2.33M Buy
+47,472
New +$2.22M 0.11% 53

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Navellier & Associates's WST Position: Q2 2022 in Review

Navellier & Associates sold out of West Pharmaceutical (WST) in Q2 2022, closing a stake of 41,237 shares — an estimated $16.9M sold.

Navellier & Associates first reported a position in WST in Q4 2013 and held it in 12 quarters. The position peaked at $20.1M in Q4 2021. 656 funds tracked by Wall St. Rank hold WST as of Q2 2022.

  • Navellier & Associates reported no remaining West Pharmaceutical position as of Q2 2022 after selling out during the quarter.
  • Navellier & Associates sold 41,237 West Pharmaceutical shares in Q2 2022, an estimated $16.9M.
  • Navellier & Associates first reported a position in West Pharmaceutical in Q4 2013 and held it in 12 quarters.
  • Navellier & Associates's West Pharmaceutical position peaked at $20.1M in Q4 2021.
  • 656 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2022.

Based on Navellier & Associates's 13F filing for Q2 2022, filed 12 Aug 2022.